Fundraising FoxVeltro Argento — 2021 Investments
1 investments dated 2021 · listed companies and verified rows first · show all
Fractyl develops therapies for obesity and type 2 diabetes, focusing on non-drug-based approaches rooted in understanding metabolic disease mechanisms.
BiotechHealthtechMedical DevicesLexington, US
Jay Caplan(Founder)inHarith Rajagopalan(Co-Founder and CEO)inLISA DAVIDSON(Executive Officer)inDiane Marcou(Executive Officer)in
BoardAllan Will(Director)inNimesh Shah(Director)in
Board seatMarc Elia· per SEC Form D · $100M raise · filed Jun 2021
Co-investorsBessemer Venture PartnersCatalio Capital Management, LPEmergent Medical Partners, LLPGeneral CatalystMithril Capital ManagementDomain Associates+1 more
.png)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.